Working Together to 'Stay in the Game'
Pharma Giants Combine HIV Pipelines into New Company
By Jennifer Boggs
Despite rumors (or perhaps hopes) that GlaxoSmithKline plc might follow recent news from Pfizer Inc. and Merck & Co. Inc. with its own mega-merger, the London-based pharma firm has opted for a more modest venture, pooling its HIV portfolio with Pfizer's in an unusual display of cooperation between pharmaceutical competitors. (BioWorld Today)